



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

**Reagent:** NIH-3T3 CD4+ CXCR4+ Cells

**Catalog Number:** 3948

**Lot Number:** 042041

**Release Category:** C

**Provided:** 1 vial (2 x 10<sup>6</sup>) frozen cells. Viability is 96%.

**Propagation Medium:** DMEM, 90%; fetal bovine serum, 10%. Supplement with pen/strep (**Note:** G418 and puromycin-sensitive).

**Freeze Medium:** Fetal bovine serum, 90%; DMSO, 10%.

**Sterility:** Negative for bacteria, fungi, and mycoplasma.

**Description:** NIH-3T3 cells expressing human CD4 and human CXCR4.

**Special Characteristics:** NIH-3T3 cells were stably transduced with the MLV MX-CD4 retroviral vector and sorted for high CD4 expression. Cells were subsequently transduced with MX-CXCR4 and sorted for high CXCR4 expression. Human CD4 and CXCR4 expression are each directed by the MX vector and BABE vector MLV LTR elements. Note: there is no selectable drug resistance marker encoded by the MX vector.

Cell line for HIV/SIV infections. As murine cells do not replicate HIV/SIV efficiently, these cells are typically used for infections with HIV/SIV Env pseudotyped vectors (ex: HIV-luc), or in syncytium assays, but not with replication-competent virus infections.

Alternate names: 3T3.T4.CXCR4

**Contributor:** Dr. Dan Littman.

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**References:**

Deng H-K, Unutmaz D, KewalRamani VN, Littman DR. Expression and cloning of new receptors used by simian and human immunodeficiency viruses. *Nature* **388**:296-300, 1997.

**NOTE:**

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: NIH-3T3 CD4+CXCR4+ Cells from Dr. Dan R. Littman." Also include the reference cited above in any publications.

**Patent pending. Scientists at for-profit institutions or who intend commercial use of this reagent must contact the New York University Office of Industrial Liaison at the following email address: [abram.goldfinger@nyumc.org](mailto:abram.goldfinger@nyumc.org)**

**Last Updated**

April 02, 2019

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.